Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine | Zendy

Yaki Saciuk | Zendy; Jennifer Kertes | Zendy; Naama Shamir Stein | Zendy; Anat Zohar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Author(s) -

Yaki Saciuk,

Jennifer Kertes,

Naama Shamir Stein,

Anat Zohar

Publication year - 2021

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jiab556

Subject(s) - medicine , confidence interval , covid-19 , retrospective cohort study , virology , infectious disease (medical specialty) , outbreak , disease

A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January–February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August–October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%–93.2%) and adjusted VE was 89.1% (95% CI, 87.5%–90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research